The purpose of this study is to determine weather Remegal in fixed dosage 1500 mg/daily is
effictive and safe in patients with epilepsy with partial seizures
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01749046
Ages eligible for Study
18 Years to 65 Years
Genders eligible for Study
Accepts Healthy Volunteers
Man or woman, aged from 18 to 65
Diagnosis of epilepsy with simple and/or complex partial seizures both with or without secondary generalization based on the ILAE classification
Results of at least one prior electroencephalogram (EEG) and magnetic resonance imaging (MRI)/computerized tomography scan no more than 5 years should confirm the diagnostic of partial seizures
If seizures are simple partial ones, only patients with motor signs must be enrolled
The onset date of partial seizures according to patient's report must be at least 2 years
The patient must report an average of at least 8 partial seizures per 56 days prior to the baseline visit
The patient must not have seizure-free period longer than 21 days during the 8 weeks prior to the baseline visit (i.e between V1 and V2)
Patients must have been treated with at least 2 different AEDs within the last 2 years prior to the screening visit
The patient is capable and would like to respect all protocol requirements, include to be available for the doctor's calls and doctor's appointments at any time, follow through all protocol procedures
The patient agrees to self - report each seizure he has experienced between 2 visits, accurately and thoroughly, in a diary he'll be provided with
Patients suffering from non-epileptic seizures
Patients having seizures that can't be counted due to clustering.
History of primary generalized seizures
History of status epilepticus within 12 months prior to the screening visit
The patient has received not permitted concomitant medications
The patient has a progressive structural lesion in the CNS, or a progressive encephalopathy
The patient is pregnant (or planning to become pregnant during the study) or is a lactating woman
The patient has used Remegal previously or participated in a clinical study within 24 weeks prior to the screening visit
The patient has experienced of any somatic disorders or psychiatric diseases and conditions which, in the opinion of the investigator, lead to health worsening or influence on the patient ability to participate in the actual clinical study
Vulnerable patients and individuals of majority age who are subject to legal protection or unable to express their consent
The patient has a history of chronic alcohol consumption or drug abuse within 2 years prior to the screening visit
The patient has a known history of a severe anaphylactic reaction or severe changes in blood tests
ALT, AST, alkaline phosphatise, total bilirubin or serum creatinine level ≥ 2 times the upper limit of normal ranges
Clinically important abnormalities on physical examination, vital signs, ECG or laboratory test results per-formed/obtained at the screening visit that may interfere with patient's safety, compliance, or study evaluations, ac-cording to the Investigator's opinion
The patient has a clinically significant disease, surgical condition or recent chronic consumption of non-AED medications (within 4 weeks prior to the screening visit) that might be reasonably expected to interfere with drug absorption, distribution, metabolism, excretion
QTc interval on the ECG performed at the screening visit above 500 ms
Diseases or concomitant medications that may prolong QTc interval
All locations for NCT01749046
Russian Federation (9)
Sverdlovsk region neuropsychiatric clinic
Ekaterinburg, Russian Federation, 620036
Region psychiatric clinic
Kemerovo, Russian Federation, 650036
Moscow regional psychiatric hospital
Moscow, Russian Federation, 127083
State Medical University
Novosibirsk, Russian Federation, 630091
State psychiatric hospital №6
Saint-Petersburg, Russian Federation, 193167
State Medical University
Samara, Russian Federation, 443099
Republican psychiatric dispensary
Saransk, Russian Federation, 430030
State Medical Academy
Smolensk, Russian Federation, 214019
Medical unit of disel equipment
Yaroslavl, Russian Federation, 150007
View full eligibility
Tris trial is registered with FDA with number: NCT01749046. The sponsor of the trial is Valexfarm and it is looking for 224 volunteers for the current phase.
Official trial title: Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.